- Regulatory Status
- RUO
- Other Names
- CD27 ligand, CD70, Ki-24 antigen, TNFSF7
-
Human CD27L binds to immobilized CD27 (2 µg/ml) in a dose dependent manner. The ED50 = 8 - 30 ng/ml.
| Cat # | Size | Price | Quantity Check Availability | ||
|---|---|---|---|---|---|
| 553404 | 25 µg | $147.00 | |||
Select size of product is eligible for a 40% discount! Promotion valid until December 31, 2024. Exclusions apply. To view full promotion terms and conditions or to contact your local BioLegend representative to receive a quote, visit our webpage.
CD27L is a 50 kD type II transmembrane glycoprotein and member of the tumor necrosis factor superfamily. Human CD27L and its mouse counterpart share about 56% sequence homology. The interaction of CD27L and CD27, a protein of the TNF receptor superfamily expressed on NK cells and subsets of T and B cells, provides co-stimulatory signals that are required for T cell proliferation, clonal expansion and development of effector T cells. CD27L-CD27 interaction on mouse B cells, on the other hand, has been shown to inhibit terminal differentiation of B cells into plasma cells. CD27L expression in mice is induced by B cell receptor activation in B cells, and at low levels by T cell receptor activation in T cells. CD27 interaction with recombinant soluble CD27L protein (sCD27L), showed that sCD27L enhanced IFN-γ secretion by CD56 (bright) NK cells in the presence of IL-12, and these NK cells were able to suppress HCV replication. Also, CD8+ T cells stimulated with sCD27L in the presence of antigen (Ag) showed enhanced proliferation and production of IL-2 and IFN-γ in vitro. In addition, administration of Ag and sCD27L induced expansion of Ag-specific CD8+ T cells in vivo. Data suggestes that sCD27L is a potent stimulator of antiglioma immune responses that depend on CD8+ T cells; therefore, sCD27L might be a good candidate as adjuvant in immunotherapy trials for glioblastoma.
Product Details
- Source
- Human CD27L, amino acids (Gln39-Pro193) (Accession# NP_001243.1), was expressed in CHO cells with a N-terminal 9His tag and a linker sequence.
- Molecular Mass
- The 176 amino acid recombinant protein has a predicted molecular mass of approximately 19.3 kD. The protein migrates at about 35 kD in DTT-reducing conditions by SDS-PAGE. The predicted N-terminal amino acid is His.
- Purity
- >90%, as determined by Coomassie stained SDS-PAGE.
- Formulation
- 0.22 µm filtered protein solution is in PBS.
- Storage & Handling
- Unopened vial can be stored between 2°C and 8°C for up to 2 weeks, at -20°C for up to six months, or at -70°C or colder until the expiration date. For maximum results, quick spin vial prior to opening. The protein can be aliquoted and stored at -20°C or colder. Stock solutions can also be prepared at 50 - 100 µg/mL in appropriate sterile buffer, carrier protein such as 0.2 - 1% BSA or HSA can be added when preparing the stock solution. Aliquots can be stored between 2°C and 8°C for up to one week and stored at -20°C or colder for up to 3 months. Avoid repeated freeze/thaw cycles.
- Activity
- Human CD27L binds to immobilized CD27 (2 µg/ml) in a dose dependent manner. The ED50 = 8 - 30 ng/ml.
- Application
-
Bioassay
- Application Notes
-
BioLegend carrier-free recombinant proteins provided in liquid format are shipped on blue-ice. Our comparison testing data indicates that when handled and stored as recommended, the liquid format has equal or better stability and shelf-life compared to commercially available lyophilized proteins after reconstitution. Our liquid proteins are verified in-house to maintain activity after shipping on blue ice and are backed by our 100% satisfaction guarantee. If you have any concerns, contact us at tech@biolegend.com.
Antigen Details
- Structure
- Homotrimer
- Distribution
-
Activated T cells, B cells, NK cells, antigen presenting cells, activated plasmacytoid dendritic cells, chronic B cell lymphocytic leukemia, and large B cell lymphomas.
- Function
- Role in T cell proliferation, generation of cytolytic and memory T cells, B cell proliferation and differentiation. CD27L is induced by B cell receptor activation in B cells and downregulated by interaction with its receptor CD27.
- Ligand/Receptor
- CD27
- Bioactivity
- Human CD27L induces proliferation of PHA-activated T cells.
- Biology Area
- Cancer Biomarkers, Cell Proliferation and Viability, Immunology
- Molecular Family
- Cytokines/Chemokines, Growth Factors, Immune Checkpoint Receptors, Soluble Receptors
- Antigen References
-
1. Bowman MR, et al. 1994. J. Immunol. 152:1756.
2. Shaw J, et al. 2010. Blood. 115:3051.
3. Keller AM, et al. 2009. Blood. 113:5167.
4. Tesselaar K, et al. 1997. J. Immunol. 159:4959.
5. Akiba H, et al. 1999. J. Immunol. 162:7058.
6. Miller J, et al. 2010. J. Neurosurg. 113:280.
7. Kuka M, et al. 2013. J. Immunol. 191:2282.
8. Jang YS, et al. 2013. Clin. Immunol. 149:379.
9. Yoshino K, et al. 2013. Br. J. Haematol. 160:331. - Gene ID
- 970 View all products for this Gene ID
- UniProt
- View information about CD27L on UniProt.org